#TeamADCT connected with the #hematology community at #ASH24 around our shared goal of advancing science and innovation to improve the lives of patients with #bloodcancer. We look forward to continuing to contribute to exciting progress underway, including through work to develop next-generation ADCs for the treatment of blood cancer.
ADC Therapeutics
Biotechnologieforschung
Lausanne, Vaud, Switzerland 19.399 Follower:innen
Innovating Science. Inspiring Hope.
Info
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.
- Website
-
http://www.adctherapeutics.com
Externer Link zu ADC Therapeutics
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Lausanne, Vaud, Switzerland
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
Orte
-
Primär
Wegbeschreibung
Lausanne, Vaud, Switzerland, CH
-
Wegbeschreibung
430 Mountain Avenue
Suite #404
New Providence, NJ 94404, US
-
Wegbeschreibung
1510 Fashion Island Boulevard
Suite 205
San Mateo, CA 94404, US
-
Wegbeschreibung
QMB Innovation Centre, 42 New Road
London, E1 2AX, GB
Beschäftigte von ADC Therapeutics
Updates
-
We’re pleased to announce positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of our CD19-targeted #antibodydrugconjugate in combination with the bispecific antibody glofitamab in patients with r/r diffuse large B-cell lymphoma (#DLBCL). We will discuss these results during a conference call and live webcast today at 8:30 a.m. ET. Learn more: https://lnkd.in/en9v6u5v
-
-
We’re pleased to announce publication in The Lancet Haematology of data from the investigator-initiated Phase 2 clinical trial evaluating our CD19-targeted #antibodydrugconjugate in combination with rituximab for the treatment of r/r follicular lymphoma as presented at #ASH24. Learn more: https://lnkd.in/eKANnEtz
-
-
Attending #ASH24? Check out presentations sharing data from independent, investigator-initiated trials evaluating our CD19-targeted #antibodydrugconjugate for the treatment of r/r follicular lymphoma and r/r marginal zone lymphoma. Find presentation details here: https://lnkd.in/ejMii577
-
We will host a corporate update webcast on December 11 at 8:30 a.m. ET to provide an update on preliminary data from dose escalation of our LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of our CD19-targeted antibody drug conjugate in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (#DLBCL). Learn more and register here: https://lnkd.in/ezRzHMv6
-
-
Tomorrow, our CEO Ameet Mallik is participating in a fireside chat at the Jefferies London Healthcare Conference at 11 a.m. GMT. A #webcast will be available via the Events & Presentations page in the Investors section of our website, ir.adctherapeutics.com. #JefferiesHealthcare
-
-
In an episode of the LARVOL Onco Data Podcast, MONIKA LAMBA SAINI, our global translational pathology leader, joined Dr. Mark Gramling for a discussion of the clinical applications of artificial intelligence (#AI) in pathology and cancer research. Listen to the full episode here: https://lnkd.in/eY3-mgdG
Dr. MONIKA LAMBA SAINI joins Dr. Mark Gramling for a broader discussion beyond the usual trial-focused topics in this episode. This time, they explore the world of pathology and the latest technological advancements. Key points include: • The clinical applications of technology in pathology, where Dr. Monika shares insights from her experience in both molecular and digital pathology. • How AI is playing a role in diagnostic applications and how pathologists work and improve patient outcomes. Dr. Monika Lamba Saini, MBBS, MD, Ph.D., is the ‘Global Translational Pathology leader’ at ADC Therapeutics, where she is responsible for the scientific strategy, including the development and implementation of translational tissue-based biomarkers and using digital pathology as a tool to expedite the development pipeline. She previously served as the Director of Digital Pathology Innovation at Q2 Solutions, IQVIA, Edinburgh, where she provided stewardship of digital pathology from validation to implementation of the digital pathology systems, as well as providing pathology support for AI-based algorithms and digital image analyses. She is a pathologist-scientist with 20+ years of experience and proficiency in pathology. She comes with extensive experience in oncopathology, molecular pathology, and digital pathology with her PhD at the Université catholique de Louvain, Brussels, Belgium. She has been the principal investigator and sub-investigator of clinical trials for companion diagnostics in oncology with Cell Carta Belgium. Her experience spans across different countries and continents. She is the author and reviewer of many publications, including Lancet and Nature, and an invited speaker on international platforms. Professional interests include translational research, cancer biology, immunopathology, digital pathology, project design and management, medical writing/publications and public speaking. Tune in to hear how these developments are shaping the future of pathology and clinical diagnostics. #Oncology #Pathology #LARVOL #ClinicalData
LARVOL Onco Data Podcast with Monika Lamba Saini
www.linkedin.com
-
Today, our CEO Ameet Mallik is participating in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference at 11 a.m. ET. A #webcast will be available via the Events & Presentations page in the Investors section of our website, ir.adctherapeutics.com.
-
-
Today, we announced our third quarter 2024 financial results and provided recent operational updates. https://lnkd.in/efA6N5rn
-
-
Today, we announced independent, investigator-initiated study abstracts on our CD19-targeted #antibodydrugconjugate ZYNLONTA® have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California from December 7-10, 2024. #ASH24 https://lnkd.in/ejMii577
-
Ähnliche Seiten
Finanzierung
ADC Therapeutics
Insgesamt 11 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Kapitalerhöhung nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
105.000.000,00 $